Business
Further progress in HD consortium
Further progress in HD consortium.
About this update from Ixico Plc
[{"type":"text","content":"\n\n \n29 July 2024\nIXICO plc\n(\"IXICO\" or the \"Company\")\n \nFurther progress in HD consortium\nPresentation of biomarker results and onboarding of new consortium partner\n \nIXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience reports further progress in the Huntington's disease imaging harmonization (HD-IH) consortium deploying IXICO's AI powered IXIQ.Ai analysis platform to develop and validate imaging biomarkers for HD. HD-IH was previously announced as a partnership between the CHDI Foundation, uniQure, PTC Therapeutics, and Asklepios BioPharmaceutical, and IXICO is pleased to announce the onboarding of an additional bio-pharma partner to HD-IH in June 2024. Over the past year, the expanding partnership has made significant progress in applying IXIQ.Ai to more than 6,000 MRI scans available to the consortium and generating the data required to demonstrate the utility of the obtained biomarker measurements as clinical trial endpoints.\n \nIXICO's Dr Marina Papoutsi presented preliminary findings at the annual HD-TC conference in February 2024 in a poster entitled \"Association between regional volume change and clinical change in Huntington's disease HD-ISS Stage 2 and Stage 3 participant\". The presentation provides further evidence for the use of brain volume changes measured with IXIQ.Ai as an alternative trial endpoint to traditional clinical outcomes (surrogate endpoint). HD-IH continues to seek additional partners to expand its biomarker development program.\n \nDr Robin Wolz, Chief Scientific Officer of IXICO, commented:\n\"We are delighted with the progress made in the HD-IH consortium over the past year. The results presented at the HD-TC conference show how the initial data generated via this partnership provides additional evidence of the impact that MRI-based biomarkers have in HD clinical development. This further expansion in the number of HD-IH biopharmaceutical partners demonstrates the value this collaboration provides to the industry.\n \nBy completing the analysis of the available data over the remainder of 2024 and focusing on the resulting biomarker evidence, the consortium will provide unique scientific understanding and insights for successful operational implementation of those measurements in clinical ...